Scientists have identified a previously unrecognized inherited form of prostate cancer that, although extremely rare, can lead to aggressive disease relatively early in life. The discovery, made by researchers at the University of British Columbia (UBC), could help doctors identify families with a heightened genetic risk and detect cancer before it spreads.
Most cancers develop as genetic changes build up in cells over time. However, approximately 5% to 10% are associated with inherited mutations that can be passed from parents to their children, creating a cancer risk that may extend across generations.
Among the most familiar examples are mutations in the BRCA1 and BRCA2 genes. These inherited changes can substantially raise the likelihood of breast, ovarian, pancreatic, and prostate cancers. Testing for BRCA mutations has reshaped cancer prevention and treatment by allowing people with elevated risks to receive earlier screening and preventive care.
Now, a study published in Cancer Discovery points to another gene, CDK12, as a potentially important marker of inherited prostate cancer risk. After examining genetic information from more than 4,500 people with aggressive prostate cancer, the researchers discovered five unrelated men with inherited mutations in CDK12. Every one of these men developed metastatic prostate cancer between ages 44 and 62, meaning the cancer had spread beyond the prostate.
“What’s striking is that every patient we identified with this inherited mutation had already developed metastatic disease by the time they were diagnosed,” said senior author Dr. Alexander Wyatt, associate professor of urologic sciences in the UBC faculty of medicine and UBC President’s Excellence Chair in Precision Oncology. “The opportunity now is to identify these families earlier and give people the chance to benefit from enhanced screening, when there are still curative treatment options.”
A Hidden Genetic Cause of Aggressive Prostate Cancer
The discovery challenges a longstanding assumption about CDK12. Scientists previously believed that harmful changes in this gene developed spontaneously inside cancer cells rather than being inherited from a parent.
To investigate whether the inherited mutations were actually contributing to the disease, the team examined the patients’ tumors for a distinctive pattern of genetic damage associated with loss of CDK12 function. This molecular fingerprint helped connect the inherited mutations to the development of their cancers.
“The tumors provided us with a genetic signature that pointed directly back to CDK12,” said lead author Dr. Sofie Tolmeijer, a postdoctoral fellow in the Wyatt lab. “It gave us compelling evidence that these inherited mutations were playing a direct role in causing their cancer.”
The findings emerged from a broad international research effort involving UBC, BC Cancer, the Vancouver Coastal Health Research Institute, and the University of Washington, along with scientists at institutions in Australia, the Netherlands, Spain, and Belgium.
Despite the potentially serious consequences, inherited CDK12 mutations appear to be exceptionally uncommon. The researchers found them in approximately one out of every 1,000 people with aggressive prostate cancer. Even at that low frequency, they estimate that hundreds of families around the world could be affected.
“While this mutation is extremely rare, the discovery could be lifesaving for the families who carry it,” said Dr. Tolmeijer. “Finding one person with an inherited mutation gives us the opportunity to identify other family members at risk and help them take action before cancer develops or spreads.”
Genetic Testing Could Help Detect Prostate Cancer Earlier
One of the most promising implications of the discovery is that doctors may not need to develop entirely new testing technology to put the findings into practice.
The researchers recommend including CDK12 in standard genetic testing panels used to assess hereditary prostate cancer risk. These panels examine multiple genes associated with inherited cancer susceptibility, helping identify individuals who may benefit from closer medical monitoring.
Importantly, the clinical technology required to detect CDK12 mutations already exists. That could make expanding genetic testing relatively straightforward, potentially reducing the time and expense needed to bring the discovery into routine patient care.
“One of the most exciting aspects of this discovery is that we already have the technology needed to act on it,” said Dr. Wyatt, who is also a senior research scientist at the Vancouver Prostate Centre and senior scientist at BC Cancer. “Adding CDK12 to existing genetic tests is relatively straightforward, which means this discovery could move from the research lab into clinical care much more quickly.”
Could the Same Mutation Increase Ovarian Cancer Risk?
The study also uncovered clues suggesting that inherited CDK12 mutations might be associated with ovarian cancer, although more research is needed to establish whether they increase the risk.
Several of the men with inherited CDK12 mutations had relatives with a history of ovarian cancer. The investigators also identified another person who had ovarian cancer and carried an inherited CDK12 mutation. Analysis of that person’s tumor revealed the same characteristic genetic signature seen in the prostate cancer cases.
Together, these observations suggest that CDK12 could potentially play a role in hereditary cancer risk beyond the prostate. Further studies will be needed to determine how strongly the mutations are associated with ovarian cancer and whether they should influence screening recommendations.
For families carrying these rare mutations, the potential benefits of identifying their genetic risk could be substantial. Earlier testing may give relatives the opportunity to receive closer surveillance and, if cancer develops, begin treatment before it reaches an advanced stage.
“With the right genetic testing and screening programs, we envision a future where no one who inherits one of these mutations dies from cancer,” said Dr. Wyatt.
The research received funding from the Prostate Cancer Foundation, Terry Fox Research Institute, Canadian Cancer Society, Canadian Institutes of Health Research, Michael Smith Health Research BC, U.S. National Institutes of Health, BC Cancer Foundation, and other funding partners.
Source: www.sciencedaily.com



